Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BMS-986442 · AGEN1777

Bispecific antibody · Immune activation, directed at TIGIT and CD96 · developed by Agenus

Phase 1 Most advanced trial (none active)

AGEN Developer

1 Registered trials

What is BMS-986442?

BMS-986442 is an Fc-enhanced bispecific antibody that binds TIGIT and CD96, immune checkpoint inhibitors on T cells and NK cells. By blocking TIGIT and CD96 signaling, it enhances CD226-mediated costimulation and restores immune function against cancer cells. It is studied in advanced cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AGEN1777
Drug type: Bispecific antibody
Targets: TIGIT, CD96, CD112 (NECTIN2) (binding partner it blocks), CD155 (PVR) (binding partner it blocks), CD226 (binding partner it blocks)
Mechanism: Immune activation, directed at TIGIT and CD96
Pathways: immune activation, T-cell-mediated immune response, NK cell activation
Therapy area: Oncology
Developer: Agenus Inc. (AGEN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05025085	Phase 1	Advanced Cancer	Completed	AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Cancer

Other drugs acting on TIGIT / CD96

Dargistotug Phase 2 Domvanalimab Phase 2 Rilvegostomig Phase 3 TAB006 Phase 1 Tiragolumab Phase 1/2

More from Agenus

AGEN1223 Phase 1 AGEN1571 Phase 1 AGEN2017 Phase 1 AGEN2373 Phase 1/2 Balstilimab Phase 2/3 Botensilimab Phase 2/3 QS21 Phase 2 Vitespen Phase 2 Zalifrelimab Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AGEN page.

Follow AGEN, the company behind BMS-986442

See AGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AGEN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z